A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine

C. Uberti Foppa, T. Bini, G. Gregis, A. Lazzarin, R. Esposito, M. Moroni

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Fourteen patients with AIDS and toxoplasmic encephalitis, who could not be treated with the standard regimen of pyrimethamine and a sulfonamide due to a previous history of bone marrow suppression and severe allergic reactions to sulfonamides, were treated with oral clindamycin and pyrimethamine. All 14 patients received a 100 mg loading dose of pyrimethamine orally followed by 50 mg/day plus clindamycin orally (600-900 mg q8h). The duration of primary treatment ranged from 6 to 8 weeks. All patients also received folinic acid (15 mg/day orally). Maintenance therapy consisted of 25 mg/day of pyrimethamine and clindamycin (300 mg q6h or 450 mg q8h) A complete or partial clinical or neuroradiological response was observed in all patients at the end of two months of primary therapy. Ten of 14 patients showed complete resolution of clinical signs, and 8 of 14 patients showed complete resolution of neuroradiologic signs. All 14 patients continued the maintenance regimen, and although there were no relapses, symptoms that had not resolved by the end of the second month of acute therapy tended to remain unchanged.

Original languageEnglish
Pages (from-to)187-189
Number of pages3
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 1991

Fingerprint

Pyrimethamine
Clindamycin
Encephalitis
Retrospective Studies
Sulfonamides
Therapeutics
Leucovorin
Hypersensitivity
Acquired Immunodeficiency Syndrome
Bone Marrow
Maintenance
Recurrence

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. / Foppa, C. Uberti; Bini, T.; Gregis, G.; Lazzarin, A.; Esposito, R.; Moroni, M.

In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 10, No. 3, 03.1991, p. 187-189.

Research output: Contribution to journalArticle

@article{c64577091d0f43cf985d5a3a888c1ddf,
title = "A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine",
abstract = "Fourteen patients with AIDS and toxoplasmic encephalitis, who could not be treated with the standard regimen of pyrimethamine and a sulfonamide due to a previous history of bone marrow suppression and severe allergic reactions to sulfonamides, were treated with oral clindamycin and pyrimethamine. All 14 patients received a 100 mg loading dose of pyrimethamine orally followed by 50 mg/day plus clindamycin orally (600-900 mg q8h). The duration of primary treatment ranged from 6 to 8 weeks. All patients also received folinic acid (15 mg/day orally). Maintenance therapy consisted of 25 mg/day of pyrimethamine and clindamycin (300 mg q6h or 450 mg q8h) A complete or partial clinical or neuroradiological response was observed in all patients at the end of two months of primary therapy. Ten of 14 patients showed complete resolution of clinical signs, and 8 of 14 patients showed complete resolution of neuroradiologic signs. All 14 patients continued the maintenance regimen, and although there were no relapses, symptoms that had not resolved by the end of the second month of acute therapy tended to remain unchanged.",
author = "Foppa, {C. Uberti} and T. Bini and G. Gregis and A. Lazzarin and R. Esposito and M. Moroni",
year = "1991",
month = "3",
doi = "10.1007/BF01964458",
language = "English",
volume = "10",
pages = "187--189",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",
number = "3",

}

TY - JOUR

T1 - A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine

AU - Foppa, C. Uberti

AU - Bini, T.

AU - Gregis, G.

AU - Lazzarin, A.

AU - Esposito, R.

AU - Moroni, M.

PY - 1991/3

Y1 - 1991/3

N2 - Fourteen patients with AIDS and toxoplasmic encephalitis, who could not be treated with the standard regimen of pyrimethamine and a sulfonamide due to a previous history of bone marrow suppression and severe allergic reactions to sulfonamides, were treated with oral clindamycin and pyrimethamine. All 14 patients received a 100 mg loading dose of pyrimethamine orally followed by 50 mg/day plus clindamycin orally (600-900 mg q8h). The duration of primary treatment ranged from 6 to 8 weeks. All patients also received folinic acid (15 mg/day orally). Maintenance therapy consisted of 25 mg/day of pyrimethamine and clindamycin (300 mg q6h or 450 mg q8h) A complete or partial clinical or neuroradiological response was observed in all patients at the end of two months of primary therapy. Ten of 14 patients showed complete resolution of clinical signs, and 8 of 14 patients showed complete resolution of neuroradiologic signs. All 14 patients continued the maintenance regimen, and although there were no relapses, symptoms that had not resolved by the end of the second month of acute therapy tended to remain unchanged.

AB - Fourteen patients with AIDS and toxoplasmic encephalitis, who could not be treated with the standard regimen of pyrimethamine and a sulfonamide due to a previous history of bone marrow suppression and severe allergic reactions to sulfonamides, were treated with oral clindamycin and pyrimethamine. All 14 patients received a 100 mg loading dose of pyrimethamine orally followed by 50 mg/day plus clindamycin orally (600-900 mg q8h). The duration of primary treatment ranged from 6 to 8 weeks. All patients also received folinic acid (15 mg/day orally). Maintenance therapy consisted of 25 mg/day of pyrimethamine and clindamycin (300 mg q6h or 450 mg q8h) A complete or partial clinical or neuroradiological response was observed in all patients at the end of two months of primary therapy. Ten of 14 patients showed complete resolution of clinical signs, and 8 of 14 patients showed complete resolution of neuroradiologic signs. All 14 patients continued the maintenance regimen, and although there were no relapses, symptoms that had not resolved by the end of the second month of acute therapy tended to remain unchanged.

UR - http://www.scopus.com/inward/record.url?scp=0025811417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025811417&partnerID=8YFLogxK

U2 - 10.1007/BF01964458

DO - 10.1007/BF01964458

M3 - Article

C2 - 2060526

AN - SCOPUS:0025811417

VL - 10

SP - 187

EP - 189

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 3

ER -